Vigmed’s rights issue fully subscribed

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION
WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS.
"The fact that Vigmed’s rights issue was oversubscribed demonstrates the strong
belief and expectations on the Company and its future development. Through this
successful rights issue, Vigmed has guaranteed the required capital to enter the
next phase – the commercialisation phase - where Vigmed will continuously and
rapidly establish distribution channels in several new markets. It is with great
confidence I look forward to a continuing strong development and expansion
during 2015”, says Lennart Holm, Chairman of the Board, Vigmed Holding AB.

The final result of Vigmed Holding AB’s (publ) (“Vigmed”) rights issue shows
that approximately 6.2 million shares, representing approximately 98.3 percent
of the offered shares, were subscribed for by the exercise of subscription
rights. In addition, subscription forms corresponding to approximately 1.3
million shares, corresponding to approximately 20.4 percent of the offered
shares, have been received. The rights issue is thereby fully subscribed.
Through the rights issue, Vigmed will receive proceeds amounting to
approximately SEK 56.4 million before transaction costs.

The shares that have not been subscribed for with preferential rights have been
allotted in accordance with the principles outlined in the prospectus. Only
those who are allotted shares will be notified. Through the rights issue
Vigmed’s share capital increases by approximately SEK 126,382.86 to
approximately SEK 884,680.11. The total number of shares increases by 6,261,904
to 43,833,332 shares.

The final day for trading in paid subscribed shares (BTAs) is expected to be 17
December 2014. The new shares are expected to start trading on NASDAQ First
North on 23 December 2014.

ABG Sundal Collier is acting as financial advisor and Mannheimer Swartling
Advokatbyrå is acting as legal advisor to Vigmed in connection with the rights
issue.

Vigmed discloses the information in this press release pursuant to the Swedish
Securities Markets Act.

The information was provided for public release on 2 December 2014 at 08:00 CET.
For further information contact:

Chairman of the board, Lennart Holm 46 70 630 8562 or CEO, Finn Ketler 46 42 600
5311
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.

Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website: www.vigmed.com/investor